What is the rationale for limiting lifetime cumulative doxorubicin exposure and how is it monitored?

• A. Does not affect the risk of cardiotoxicity; monitor with CBC.
• B. Reduces risk of late cardiomyopathy; monitor with serial echocardiograms and maintain awareness of cumulative dose.
• C. Increases risk of mucositis; monitor with oral care.
• D. Requires no monitoring beyond standard checks.

Answer: (B)

Doxorubicin causes cardiotoxicity that is strongly related to the total amount given, so limiting the lifetime cumulative exposure reduces the risk of developing late cardiomyopathy or heart failure years after treatment. Because heart damage can emerge long after therapy ends, ongoing cardiac surveillance is essential, not just during treatment. The main monitoring approach is to keep a careful tally of the cumulative dose and perform serial echocardiograms to track left ventricular function over time, allowing early detection of dysfunction and timely modification of therapy if needed. CBC monitoring targets bone marrow suppression and does not address this cardiac risk, and mucositis concerns are separate from long-term heart toxicity, so that choice doesn’t fit. Continuous standard checks alone wouldn’t capture the specialized cardiac risk or guide decisions about stopping or altering cumulative therapy.